|21.57|| -0.10 / -0.46%|
Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing novel predictive and personalized medicines and prognostic medicine tests. It operates through the following segments: Research, Molecular Diagnostics and Companion Diagnostics. The Research segment focuses on the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal and information technology. The Molecular Diagnostics segment provides testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.
|Mark C. Capone||President, Chief Executive Officer & Director|
|Gary A. King||Executive Vice President-International Operations|
|R. Bryan Riggsbee||Chief Financial Officer, Treasurer & Executive VP|
|Robert Gardner Harrison||Chief Information Officer|
|Jerry S. Lanchbury||Chief Scientific Officer|